test2

  Meet Health in Tech (HIT)  — the real deal in healthcare meets insurtech. What do they actually do? They provide a full-stack SaaS platform for small insurers (TPAs) and brokers (MGAs). Ex) If you wanted to start a small insurance business today, this platform would handle everything for you — from plan design and pricing to claims processing and risk management. ✅ Proprietary underwriting algorithms ✅ Custom insurance plan builder ✅ Automated compliance system ✅ Fully cloud-based infrastructure While legacy systems have locked traditional insurers in the past, HIT is one of the very few players helping smaller insurers go fully digital. Why is this revolutionary? Historically, insurance has been a big player’s game. It costs millions just to build the infrastructure. But HIT breaks that barrier with a subscription-based SaaS model. That means anyone can launch and operate an insurance product for a fraction of the cost. And here’s the kicker — insurance plans built using HI...

  Valneva: Lyme’s Worst Nightmare If you’re into under-the-radar biotechs with real products and FDA stamps, Valneva (VALN) deserves your full attention. It may look like a small-cap underdog, but it’s already taken down one virus—and it’s coming for another. Valneva is a French company, but you can buy its shares on the NASDAQ. So what do they do? Valneva is a French vaccine company that plays hard. They’ve already delivered vaccines for Japanese Encephalitis and Cholera, but now they’ve locked onto two viral targets: 🦟 Chikungunya – Already FDA-approved 🦠 Lyme disease – Next in line, and it’s personal First: Chikungunya? Handled. In 2023, Valneva launched VLA1553, the world’s first FDA-approved Chikungunya vaccine.  > No drama, just Valneva vs. Chikungunya. The world had no jab—Valneva said “grab.” First in class, now leading the pack. VLA1553? Already in the bag. 💼 Next Target: Lyme Disease This time, Valneva is teaming up with Pfizer to take down Lyme disease, which ...

  Xilio Therapeutics (XLO): Small Biotech with Big Potential? Xilio’s the next 100x rocket!!! unless it explodes What’s their deal? Xilio is developing  tumor-selective immunotherapies . Simply put, their drugs only “turn on” inside tumors, not in healthy tissue. This could mean fewer side effects and stronger cancer-fighting power. AbbVie and Gilead are both involved AbbVie  signed a research deal with Xilio to co-develop a  masked TNF (tumor necrosis factor) program . TNF is powerful against cancer but usually too toxic; Xilio’s tech could make it safer and more effective. Gilead Sciences  not only is interested in Xilio’s  tumor microenvironment (TME) targeting technology , but also  invested directly in the company . Gilead has been actively expanding its oncology footprint, and their investment signals strong confidence in Xilio’s approach. What’s in their pipeline? XTX101 : Tumor-activated anti-CTLA-4 antibody in clinical trials XTX202 : Tumor-se...